Review summary
Teaching objective: Evaluation and first-year care of progressive dementia of undetermined type in a 73-year-old man: history from the patient and an informant, MoCA, function (ADL and IADL), staging, depression screen, reversible-cause tests (vitamin B12, folate, TSH, blood count, metabolic panel) with syphilis and HIV testing only where indicated, a one-time brain MRI, disclosure of the diagnosis, a cholinesterase inhibitor trial with heart rate and side-effect checks, safety (driving, firearms, wandering, finances, home), avoidance of anticholinergic drugs, caregiver support with the Zarit Burden Interview, and advance care planning while he can take part, on the CMID non-Alzheimer's dementia and Alzheimer's disease monographs with the AAN dementia and driving parameters and the Alzheimer's Association DETeCD-ADRD guideline. Any specific cause is treated as unknown, as it is in the historical record.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| April 26, 1822 | Born in Hartford, Connecticut. | CLM-0001 |
| 1863 | Resigned from the U.S. Sanitary Commission, exhausted and ill. | CLM-0009 |
| 1872 | Chose the Belmont site for McLean Hospital. | CLM-0005 |
| 1895 | Ceased active practice because of failing memory and vitality. | CLM-0003 |
| 1897 | Spent a summer at a house on Deer Isle, Maine, laid out to stimulate his failing mental abilities. | CLM-0004 |
| 1898 | Admitted to McLean Hospital, where he spent his last five years. | CLM-0005 |
| August 28, 1903 | Died in Belmont, Massachusetts, at 81. | CLM-0002 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Frederick Law Olmsted was born in Hartford, Connecticut, on April 26, 1822. | confirmed | Frederick Law Olmsted supports |
| D | Olmsted died on August 28, 1903, in Belmont, Massachusetts, at 81. Record the death as a fact without detail. |
confirmed | Frederick Law Olmsted supports Felsted supports |
| D | Olmsted ceased active practice in 1895, a victim of failing memory and vitality; later accounts say dementia, or senility, forced his retirement, and his sons took over the firm. The anchor for the synthetic mild dementia; the retirement fixes the index year. |
confirmed | The Olmsted Firm supports Where Frederick Law Olmsted lived his last good years supports Frederick Law Olmsted supports |
| D | His health continued to fail after he retired. A trip to England did not help, and he became depressed there; a summer house built on Deer Isle, Maine, in 1897 was laid out to stimulate his decreasing mental abilities, but after one summer there his health continued to deteriorate. Documents the progression after the episode; claim only. |
confirmed | Felsted supports |
| D | Olmsted, who had chosen the Belmont site of McLean Hospital in 1872, was admitted there as a patient at the end of his life and spent his last five years there, until his death in 1903. Documents the later course, after the episode; claim only. |
confirmed | McLean Asylum supports Where Frederick Law Olmsted lived his last good years supports Frederick Law Olmsted supports Frederick Law Olmsted supports |
| D | His McLean Hospital medical record is sealed, and the cause of his decline is not known. Why the record codes dementia of unspecified type. |
confirmed | Frederick Law Olmsted supports |
| R | Any specific type of dementia (for example Alzheimer's disease or vascular dementia) is a retrospective interpretation; the cited sources say only failing memory, senility, and dementia. Not coded; the synthetic episode keeps the type undetermined. |
possible | The Olmsted Firm context Where Frederick Law Olmsted lived his last good years context Frederick Law Olmsted context |
| R | A psychiatrist has argued retrospectively that losses in his childhood, beginning with his mother's death when he was a young child, left him with post-traumatic stress, and that his late illness made it worse. Retrospective psychiatric interpretation; not coded and not used in the episode. |
possible | Frederick Law Olmsted supports |
| D | In 1863, exhausted and ill after overwork as head of the U.S. Sanitary Commission, Olmsted resigned. Past history only; the illness is not specified in the cited source. |
confirmed | Frederick Law Olmsted supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Mild dementia (major neurocognitive disorder), progressive, amnestic-predominant with executive difficulty, type undetermined; CDR global 1 | active | confirmed | active | CLM-0003, CLM-0006, CLM-0007 |
| S | Common cold, with two nights of increased confusion after an over-the-counter nighttime cold medicine containing diphenhydramine; resolved | resolved | confirmed | active | |
| S | Progressive memory loss over about two years with decline in managing his work and affairs, under evaluation for dementia or mild cognitive impairment | resolved | confirmed | active | CLM-0003, CLM-0006, CLM-0007 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-05-05 | Hemoglobin [Mass/volume] in Blood | 14.1 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-05-05 | Leukocytes [#/volume] in Blood by Automated count | 6.2 10*3/uL Reference 3.4-9.6 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-05-05 | Platelets [#/volume] in Blood by Automated count | 238 10*3/uL Reference 135-317 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-05-05 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-05-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-05-05 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 76 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-05 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-05-05 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-05-05 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-05-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-05-05 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 410 pg/mL Reference 232-1245 pg/mL |
http://loinc.org · 2132-9 |
| S | 2026-05-05 | Folate [Mass/volume] in Serum or Plasma | 12.4 ng/mL Reference >=5.9 ng/mL |
http://loinc.org · 2284-8 |
| S | 2026-05-05 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-05-05 | Total score [MoCA] | 19 | http://loinc.org · 72172-0 |
| S | 2026-05-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-09-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-09-15 | Total score [AUDIT-C] | 0 | http://loinc.org · 75626-2 |
| S | 2026-09-15 | Cholesterol [Mass/volume] in Serum or Plasma | 196 mg/dL Reference <=200 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-09-15 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-09-15 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 118 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-09-15 | Triglyceride [Mass/volume] in Serum or Plasma | 120 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-05-05 | Body height | 175 cm | 8302-2 | S |
| 2026-05-05 | Body weight | 72 kg | 29463-7 | S |
| 2026-05-05 | Body mass index (BMI) [Ratio] | 23.5 kg/m2 | 39156-5 | S |
| 2026-05-05 | Systolic blood pressure | 134 mm[Hg] | 8480-6 | S |
| 2026-05-05 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-05-05 | Heart rate | 72 /min | 8867-4 | S |
| 2026-05-05 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-05-05 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-05-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-06-02 | Body height | 175 cm | 8302-2 | S |
| 2026-06-02 | Body weight | 71.8 kg | 29463-7 | S |
| 2026-06-02 | Body mass index (BMI) [Ratio] | 23.4 kg/m2 | 39156-5 | S |
| 2026-06-02 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2026-06-02 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-06-02 | Heart rate | 70 /min | 8867-4 | S |
| 2026-06-02 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-06-02 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-06-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-08-04 | Body height | 175 cm | 8302-2 | S |
| 2026-08-04 | Body weight | 71.2 kg | 29463-7 | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 23.2 kg/m2 | 39156-5 | S |
| 2026-08-04 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-08-04 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-08-04 | Heart rate | 62 /min | 8867-4 | S |
| 2026-08-04 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-04 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-10-27 | Body height | 175 cm | 8302-2 | S |
| 2026-10-27 | Body weight | 71 kg | 29463-7 | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 23.2 kg/m2 | 39156-5 | S |
| 2026-10-27 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 2026-10-27 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-27 | Heart rate | 60 /min | 8867-4 | S |
| 2026-10-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-27 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-07-14 | Body height | 175 cm | 8302-2 | S |
| 2026-07-14 | Body weight | 71.4 kg | 29463-7 | S |
| 2026-07-14 | Body mass index (BMI) [Ratio] | 23.3 kg/m2 | 39156-5 | S |
| 2026-07-14 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 2026-07-14 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-07-14 | Heart rate | 70 /min | 8867-4 | S |
| 2026-07-14 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-07-14 | Body temperature | 37.4 Cel | 8310-5 | S |
| 2026-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-09-15 | Body height | 175 cm | 8302-2 | S |
| 2026-09-15 | Body weight | 71 kg | 29463-7 | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 23.2 kg/m2 | 39156-5 | S |
| 2026-09-15 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-09-15 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-09-15 | Heart rate | 60 /min | 8867-4 | S |
| 2026-09-15 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-15 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Never used tobacco; one glass of wine with dinner a few nights a week, stopped at the first visit on advice; no other drug use
- S Landscape architect who stepped back from his practice this year because of his memory; lives at home with family, and a primary caregiver who is not named in this record accompanies him to visits
- S Walks in the garden and the neighborhood most days with company
- S Drove locally at the first visit; no firearms in the home
- S Supports: his primary caregiver, family at home, long-time colleagues who visit, and a lifelong love of gardens and walking
Functional status
- S Katz ADL 6 of 6 (independent in bathing, dressing, toileting, transfers, continence, and feeding)
- S Lawton-Brody IADL 5 of 8: needs help with finances, medicines, and planning travel; still uses the telephone, shops with company, and helps with meals and laundry
- S Clinical Dementia Rating global 1 (mild); FAST stage 4
- S NPI-Q: mild irritability and mild apathy; no hallucinations, delusions, agitation, or night-time wandering
- S Timed Up and Go 11 seconds; no falls in the past year; normal gait
Mental status
- S Alert, courteous, and articulate; repeats questions within the visit; MoCA 19 of 30, losing points on delayed recall (1 of 5), orientation to date, clock drawing, trail-making, and verbal fluency
- S Mood low at times over losing his work; PHQ-9 score 6; denies thoughts of death or self-harm; no psychosis
Allergies and medications
Allergies
- S No known allergy
Medications
- S Donepezil 5 mg oral tablet, one tablet by mouth each morning
- S Donepezil 10 mg oral tablet, one tablet by mouth each morning
Procedures and immunizations
Procedures
- S MRI of the brain without contrast: generalized cortical atrophy beyond that expected for age, with mild bilateral medial temporal atrophy (MTA score 2) and scattered small white-matter hyperintensities (Fazekas grade 1); no infarct, hemorrhage, mass, or hydrocephalus
- S Advance care planning conversation with the patient and his caregiver, about 30 minutes
Immunizations
- S 2025-10-21: High-dose influenza vaccine, 2025-2026 season
- S 2026-09-15: High-dose influenza vaccine, 2026-2027 season
- S 2026-09-15: Pneumococcal conjugate vaccine PCV20
- S 2026-09-15: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1863: Exhaustion and illness from overwork while leading a national wartime relief commission, ending in his resignation in 1863; illness not specified in the cited source (CLM-0009)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Complete the reversible-cause tests and brain MRI and discuss the diagnosis with him and his caregiver by the four-week visit | 2026-06-02 | completed | Tests and MRI showed no reversible cause; diagnosis of mild dementia of undetermined type discussed with both |
| A safety plan in place by the three-month review: no driving, medicines supervised, finances overseen, and medical identification worn | 2026-08-04 | completed | Stopped driving after the consultation; caregiver gives medicines from a weekly organizer and oversees bill paying with his agreement; medical identification bracelet worn |
| Donepezil at 10 mg daily without side effects and with resting heart rate 55 or above by the six-month review | 2026-10-27 | completed | On 10 mg for three months; heart rate 60; no nausea, diarrhea, weight loss, or vivid dreams |
| Caregiver burden assessed and support in place by the six-month review | 2026-10-27 | completed | Zarit Burden Interview 24 at three months; caregiver education program completed and two days a week of adult day program begun |
| Name a health care agent and record his values and wishes while he can take full part, by the three-month review | 2026-08-04 | completed | Health care agent named and his wishes recorded at the three-month review |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Reversible-cause tests (blood count, metabolic panel, vitamin B12, folate, TSH) and one non-contrast brain MRI; syphilis and HIV testing only with risk factors or atypical features | completed | GL-AAN-DEM-2001, GL-ALZ-PC-2025, GL-CMID-2026 |
| Behavioral neurology consultation to confirm the diagnosis, consider the type and biomarker testing, and advise on treatment and driving | completed | GL-ALZ-SC-2025, GL-AAN-DEM-2001, GL-AAN-DRIVE-2010 |
| Donepezil trial, 5 mg daily for four to eight weeks then 10 mg, with heart rate, fainting, gastrointestinal effects, weight, and sleep checked at each visit; avoid anticholinergic drugs, first-generation antihistamines, benzodiazepines, and sleeping pills (AGS Beers Criteria) | completed | GL-CMID-2026, GL-BEERS-2023 |
| Safety: stop driving at CDR 1, keep the home free of firearms, medical identification for wandering, supervised medicines and finances, and home safety | completed | GL-AAN-DRIVE-2010, GL-CMID-2026 |
| Caregiver support: Zarit Burden Interview at diagnosis and every six to twelve months, education, adult day program and respite, and Alzheimer's Association support services | completed | GL-CMID-2026, GL-ALZ-PC-2025 |
| Monitor on the CMID dementia schedule: medication review and neuropsychiatric screen at every visit; MoCA, ADL and IADL, CDR or FAST stage, depression screen, fall risk, driving, and advance care planning yearly; repeat tests or imaging only with a sudden change | completed | GL-CMID-2026 |
| Advance care planning while he can take part: name a health care agent and record his values and wishes | completed | GL-CMID-2026, GL-ALZ-PC-2025 |
Planned encounters
- 2026-05-05 — Cognitive evaluation for progressive memory loss: history from patient and caregiver, MoCA, function, mood, safety, and reversible-cause tests (ENC-001)
- 2026-06-02 — Four-week follow-up: results and MRI review, diagnosis disclosure, and behavioral neurology consultation (ENC-002)
- 2026-07-14 — Same-day sick visit for a head cold with night-time confusion (ENC-005, unscheduled)
- 2026-08-04 — Three-month dementia review: donepezil, safety plan, caregiver burden, and advance care planning (ENC-003)
- 2026-09-15 — Subsequent annual wellness visit (ENC-006)
- 2026-10-27 — Six-month dementia review (ENC-004)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Sick Visit
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Annual Wellness Visit, Subsequent
- Progress note 06 — Focused Visit (Care-plan review)
- Behavioral Neurology referral
- Behavioral Neurology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Sick Visit (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Annual Wellness Visit, Subsequent (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Behavioral Neurology referral (XML)
- Behavioral Neurology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Frederick Law Olmsted | Wikipedia | other |
| SRC-0002 | The Olmsted Firm | Olmsted Network | other |
| SRC-0003 | Felsted | National Park Service | government |
| SRC-0004 | McLean Asylum | National Park Service | government |
| SRC-0005 | Where Frederick Law Olmsted lived his last good years | Harvard Magazine | other |
| SRC-0006 | Frederick Law Olmsted | Harvard Magazine | other |
| SRC-0007 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review. |
| provenance review | not_started | The failing memory, retirement, and later institutional care are documented; the cause is unknown and any specific type is graded R. Caregivers are unnamed, and no statement or health fact is attributed to a real relative or business partner. |
| safe messaging review | not_started | Dementia described with dignity; PHQ-9 scores below 10 with no thoughts of self-harm, so no safety assessment is required; the documented depression abroad and the institutional care are claims only, marked sensitive. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.